Role of HIV Rev in Reactivation from Latency
HIV Rev 在潜伏期重新激活中的作用
基本信息
- 批准号:9534516
- 负责人:
- 金额:$ 20.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-26 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAnti-Retroviral AgentsAutologousCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCellsCoculture TechniquesDataElementsEngineeringGoalsHIVHighly Active Antiretroviral TherapyImmuneImmune EvasionKnowledgeLaboratoriesLatent VirusLymphocyteMeasuresMemoryModelingNewly DiagnosedPatientsPeptidesPharmaceutical PreparationsPopulationPredispositionProcessProductionProvirusesRNA BindingReporterResearchRoleSystemT-LymphocyteTestingVariantViralViral ProteinsViral Structural ProteinsVirionVirusVirus ActivationVirus LatencyVirus Replicationcytotoxicdesignexperimental studyimmune clearanceimprovednef Proteinperipheral bloodreactivation from latencyrev Genes
项目摘要
Project Summary/Abstract
Efforts to achieve a cure for HIV continue to be stymied by the persistence of inducible proviruses in
latently infected cells. If the cells constituting the proviral reservoir can be induced to actively produce virus,
then the reservoir could potentially be cleared by means of native immune killing or extrinsic therapies. Efforts
in this direction to date have been hampered by an inability to reliably stimulate the entire latent reservoir such
that this clearance can be achieved. One potential mechanism that could contribute to suboptimal latent cell
activation and clearance is variation in the HIV Rev/RRE regulatory axis.
Recent data from our laboratory have indicated that Rev/RRE functional activity varies greatly among
primary isolates and that rather than acting as an on-off switch, Rev/RRE activity modulates viral replication.
Upon re-activation, proviruses in latently infected cells with less functionally active Rev/RRE pairs would be
expected to have decreased production of many viral proteins and virus particles, while continuing to produce
normal levels of the immune modulatory viral Nef protein. Cells containing proviruses with low Rev/RRE
activity may therefore be more difficult to clear in the so-called “kick-and-kill” strategies for cure.
Experiments in this proposal are designed to test this hypothesis. Subaims1a and 1b will utilize an
established latency model and a set of engineered viruses that have altered Rev/RRE activity to directly
assess how reactivation of latently infected cells with various latency reactivating agents affects viral activation
and outgrowth. Subaim1c will measure Rev/RRE function in replication competent viruses isolated from
patients' latent cells. These experiments will determine how Rev/RRE function varies compared to sequences
derived from the peripheral blood of newly diagnosed patients, and whether there has been any selection with
respect to levels of Rev/RRE functional activity. Specific Aim 2 will measure CTL killing of latency-reactivated
cells to directly determine how Rev/RRE activity variation influences the susceptibility of the cells to immune
elimination.
Improved understanding of how the Rev-RRE regulatory system functions in viral latency may be one
key to understanding why “kick-and-kill” cure strategies have been unsuccessful to date. This information
could in turn be used to optimize the “kick” by modulating the Rev-RRE activity of latent virus. The proposed
study thus has direct bearing on the most promising strategy to date to cure HIV and could provide crucial
knowledge to advance this thus-far elusive goal.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARIE-LOUISE HAMMARSKJOLD其他文献
MARIE-LOUISE HAMMARSKJOLD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARIE-LOUISE HAMMARSKJOLD', 18)}}的其他基金
Host Factors That Restrict HIV mRNA With Retained Introns
限制 HIV mRNA 保留内含子的宿主因素
- 批准号:
10480987 - 财政年份:2022
- 资助金额:
$ 20.13万 - 项目类别:
Effects of HIV Rev on Host Cell Gene Expression
HIV Rev 对宿主细胞基因表达的影响
- 批准号:
10546602 - 财政年份:2022
- 资助金额:
$ 20.13万 - 项目类别:
Host Factors That Restrict HIV mRNA With Retained Introns
限制 HIV mRNA 保留内含子的宿主因素
- 批准号:
10553285 - 财政年份:2022
- 资助金额:
$ 20.13万 - 项目类别:
Effects of HIV Rev on Host Cell Gene Expression
HIV Rev 对宿主细胞基因表达的影响
- 批准号:
10673153 - 财政年份:2022
- 资助金额:
$ 20.13万 - 项目类别:
Functional Variation of Rev and RRE Activity During HIV Infection
HIV 感染期间 Rev 和 RRE 活性的功能变化
- 批准号:
8465556 - 财政年份:2013
- 资助金额:
$ 20.13万 - 项目类别:
Functional Variation of Rev and RRE Activity During HIV Infection
HIV 感染期间 Rev 和 RRE 活性的功能变化
- 批准号:
8858647 - 财政年份:2013
- 资助金额:
$ 20.13万 - 项目类别:
相似海外基金
RESISTANCE OF HIV-1 TO ANTI-RETROVIRAL AGENTS
HIV-1 对抗逆转录病毒药物的耐药性
- 批准号:
3030975 - 财政年份:1993
- 资助金额:
$ 20.13万 - 项目类别:
POLYMERICS DELIVERY SYSTEMS FOR ANTI-RETROVIRAL AGENTS
抗逆转录病毒药物的聚合物递送系统
- 批准号:
3489187 - 财政年份:1990
- 资助金额:
$ 20.13万 - 项目类别:
DEVELOPMENTAL VIROLOGY RESEARCH--RESISTANCE TO ANTI-RETROVIRAL AGENTS
发育病毒学研究——抗逆转录病毒药物的耐药性
- 批准号:
2335293 - 财政年份:
- 资助金额:
$ 20.13万 - 项目类别: